Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
P/E ratio for Intra-Cellular Therapies, Inc. (ITCI)
P/E ratio as of 2023: -49.16
According to Intra-Cellular Therapies, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -49.16. At the end of 2022 the company had a P/E ratio of -19.42.
P/E ratio history for Intra-Cellular Therapies, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -49.16 |
| 2022 | -19.42 |
| 2021 | -14.97 |
| 2020 | -9.86 |
| 2019 | -12.82 |
| 2018 | -4.02 |
| 2017 | -6.84 |
| 2016 | -5.60 |
| 2015 | -18.48 |
| 2014 | -16.48 |
| 2013 | -9.62 |
| 2012 | -20.03 |